Moors & Cabot Inc. Sells 293 Shares of Thermo Fisher Scientific Inc. $TMO

Moors & Cabot Inc. reduced its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 8.7% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 3,071 shares of the medical research company’s stock after selling 293 shares during the period. Moors & Cabot Inc.’s holdings in Thermo Fisher Scientific were worth $1,245,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Revolve Wealth Partners LLC boosted its position in shares of Thermo Fisher Scientific by 4.2% during the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after buying an additional 20 shares during the last quarter. Lafayette Investments Inc. boosted its holdings in shares of Thermo Fisher Scientific by 2.4% during the 2nd quarter. Lafayette Investments Inc. now owns 927 shares of the medical research company’s stock valued at $376,000 after acquiring an additional 22 shares during the last quarter. Rossmore Private Capital raised its holdings in shares of Thermo Fisher Scientific by 0.5% during the first quarter. Rossmore Private Capital now owns 4,652 shares of the medical research company’s stock valued at $2,315,000 after purchasing an additional 24 shares during the last quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH lifted its position in Thermo Fisher Scientific by 3.1% during the second quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH now owns 803 shares of the medical research company’s stock valued at $326,000 after purchasing an additional 24 shares during the period. Finally, Somerville Kurt F boosted its holdings in Thermo Fisher Scientific by 1.6% in the second quarter. Somerville Kurt F now owns 1,605 shares of the medical research company’s stock worth $651,000 after purchasing an additional 25 shares during the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have recently weighed in on TMO shares. HSBC reissued a “hold” rating and set a $510.00 price target on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Weiss Ratings reissued a “hold (c)” rating on shares of Thermo Fisher Scientific in a report on Tuesday, October 14th. Raymond James Financial restated an “outperform” rating and set a $535.00 price target (up from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Hsbc Global Res cut shares of Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 24th. Finally, Leerink Partners boosted their target price on shares of Thermo Fisher Scientific from $545.00 to $580.00 and gave the company an “outperform” rating in a research report on Wednesday, October 22nd. Nineteen research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $601.65.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 17,104 shares of the stock in a transaction dated Friday, October 24th. The stock was sold at an average price of $573.54, for a total value of $9,809,828.16. Following the completion of the sale, the chief executive officer directly owned 113,762 shares in the company, valued at approximately $65,247,057.48. This trade represents a 13.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the completion of the transaction, the chief accounting officer owned 2,319 shares in the company, valued at approximately $1,142,408.97. This trade represents a 14.24% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 36,420 shares of company stock valued at $19,980,884. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Stock Performance

Shares of TMO opened at $566.47 on Friday. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $610.97. The firm has a market capitalization of $212.83 billion, a P/E ratio of 32.73, a PEG ratio of 3.27 and a beta of 0.82. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.50 and a quick ratio of 1.11. The business has a fifty day moving average of $516.99 and a 200 day moving average of $461.35.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.50 by $0.29. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The company had revenue of $11.12 billion for the quarter, compared to the consensus estimate of $10.90 billion. During the same quarter last year, the firm posted $5.28 earnings per share. The firm’s revenue was up 4.9% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. As a group, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, January 15th. Shareholders of record on Monday, December 15th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 0.3%. The ex-dividend date is Monday, December 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 9.94%.

Thermo Fisher Scientific declared that its Board of Directors has authorized a stock buyback plan on Thursday, November 6th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical research company to reacquire up to 2.4% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s leadership believes its shares are undervalued.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.